Sulfinpyrazone and postoperative deep vein thrombosis.
Small doses of subcutaneous heparin and infusions of dextran both reduce the incidence of fatal pulmonary embolism after elective general surgery. But both methods have disadvantages. Therefore, the protection against deep vein thrombosis afforded by sulfinpyrazone, a drug which can be taken by mouth as well as by injection, was assessed in a prospective study of 119 patients undergoing elective general or urological surgery. The prophylactic administration of sulfinpyrazone was compared with the effects of small doses of sodium heparin and infusions of dextran-70. The 125I-fibrinogen test was carried out in all patients during their hospitalization. Deep vein thrombosis was diagnosed in 13 of 30 patients (43%) who received sulfinpyrazone, in 9 of 29 (31%) receiving dextran-70 and in 2 of 22 (9%) having subcutaneous heparin. The difference between the sulfinpyrazone and heparin groups was statistically significant (p less than 0.01). Sulfinpyrazone in the dose used in this trial was not effective in reducing the incidence of deep vein thrombosis during elective general surgery.
D000284:Administration, Oral; D000328:Adult; D003911:Dextrans / Q000008:administration & dosage / Q000627:therapeutic use; D004341:Drug Evaluation; D005340:Fibrinogen; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D011183:Postoperative Complications / Q000517:prevention & control*; D011446:Prospective Studies; D013442:Sulfinpyrazone / Q000008:administration & dosage / Q000627:therapeutic use*; D013924:Thrombophlebitis / Q000517:prevention & control*
D003911:Dextrans; D005340:Fibrinogen; D006493:Heparin; D013442:Sulfinpyrazone